Compare GALT & FNRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GALT | FNRN |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 295.8M |
| IPO Year | 2008 | 2000 |
| Metric | GALT | FNRN |
|---|---|---|
| Price | $4.04 | $17.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 340.4K | 88.2K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | 2.42 |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $15.93 |
| 52 Week High | $7.13 | $19.25 |
| Indicator | GALT | FNRN |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 38.15 |
| Support Level | $2.74 | $15.93 |
| Resistance Level | $4.35 | $17.87 |
| Average True Range (ATR) | 0.28 | 0.35 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 72.03 | 16.74 |
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.